Seeing little light in a dark environment for the small, medical-device company, managers at SpectraScience Inc. have decided to halt operations and have filed for bankruptcy protection while they ...
SAN DIEGO, CA--(Marketwired - February 02, 2016) - SpectraScience, Inc. (SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it had ...
SAN DIEGO, CA--(Marketwired - May 19, 2015) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today a recently ...
SpectraScience and PENTAX Medical Announce Expanded Distribution of WavSTAT4 Optical Biopsy System i
SAN DIEGO--(BUSINESS WIRE)-- SpectraScience, Inc. (OTCQB:SCIE), a San Diego-based medical device company and PENTAX Europe GmbH (PENTAX Medical herein after) jointly announce that they have agreed on ...
SAN DIEGO, CA--(Marketwired - November 30, 2015) - SpectraScience, Inc. (SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it had ...
PENTAX Medical, the Japan-based endoscopic device division of the Hoya Group, and SpectraScience, a medical device company based in San Diego, have announced the growth of WavSTAT4 Optical Biopsy ...
SpectraScience Inc. Annual stock financials by MarketWatch. View the latest SCIE financial statements, income statements and financial ratios.
SAN DIEGO, March 10 SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, announced that its CEO, Jim Hitchin, was recently featured in an MDDI Magazine article ...
SpectraScience has acquired the assets of Oncoscope. 1. SpectraScience is a medical device company that develops products using light technologies to detect and diagnose cancers. 2. Oncoscope ...
SAN DIEGO, CA--(Marketwired - Dec 2, 2014) - SpectraScience, Inc. (OTCQB: SCIE), a San Diego-based medical device company, today announced that its Board of Directors has appointed Rand Mulford to its ...
SpectraScience exited the quarter with $1.38 million in cash and equivalents, compared to $2.58 million at 6/30/2011. Cash used in operations was $1.04 million and $2.23 million in the three and nine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback